Pfizer's Talzenna/Xtandi Combo Improves Survival Outcomes In Metastatic Castration-Resistant Prostate Cancer

Zinger Key Points

In mCRPC patients, Talzenna + Xtandi cut death risk by 20%, extending median OS to 45.8 months vs. 37.0 months with Xtandi alone.
In HRR-mutated mCRPC, Talzenna + Xtandi reduced death risk by 38%, with a median OS of 45.1 months vs. 31.1 months for Xtandi alone.
Get access to your new suite of high-powered trading tools, including real-time stock ratings, insider trades, and government trading signals.

On Thursday, Pfizer Inc. PFE revealed results from the Phase 3 TALAPRO-2 study of Talzenna (talazoparib) in combination with Xtandi (enzalutamide).

The trial demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo plus Xtandi in patients with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations.

Also Read: Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo

The TALAPRO-2 study evaluated two sets of patients, unselected (cohort 1) and selected for HRR gene-mutations (cohort 2).

Overall survival was a prespecified, alpha-protected key secondary endpoint.

After more than four years of median follow-up (52.5 months), the median OS in cohort 1 was 45.8 months with Talzenna in combination with Xtandi and 37.0 months with Xtandi and placebo, representing a 20% reduction in the risk of death, representing a nearly 9-month gain in median OS versus standard of care Xtandi.

In Cohort 2, a statistically significant and clinically meaningful improvement in OS was observed in patients with HRR-mutated mCRPC.

At a median follow-up of 44.2 months, the median OS was 45.1 months with Talzenna in combination with Xtandi and 31.1 months with Xtandi and placebo, a 38% reduction in the risk of death, representing a 14-month gain in median OS versus standard of care Xtandi in a patient population with a historically poor prognosis.

The OS improvement in the HRR-mutated population was observed in patients with BRCA and non-BRCA gene alterations.

At the time of the final analysis, updated radiographic progression-free survival (rPFS) and other secondary efficacy endpoints demonstrated maintained clinical benefit in both cohorts and were consistent with the primary analyses previously reported and published in The Lancet and Nature Medicine.

Price Action: Pfizer stock is up 0.04% at $25.65 at last check Friday.

Read Next: